Managing Immunotherapy Protocols

Managing Immunotherapy Protocols

Guides immune checkpoint inhibitor management with irAE recognition and grading.

Why This Skill Exists

Immune checkpoint inhibitors (ICIs) — anti-PD-1 (nivolumab, pembrolizumab, cemiplimab), anti-PD-L1 (atezolizumab, durvalumab, avelumab), and anti-CTLA-4 (ipilimumab, tremelimumab) — are now approved across more than 20 cancer types and have become the backbone of oncology treatment. However, their mechanism of action (releasing immune system brakes) causes a unique toxicity profile: immune-related adverse events (irAEs) that can affect any organ system and range from mild to fatal.

ASCO/NCCN irAE management guidelines provide evidence-based algorithms for recognition, grading, and treatment of irAEs. Failure to recognize irAEs early leads to preventable deaths — immune-related myocarditis has a mortality rate of 25–50% if not promptly treated. Conversely, overreaction to mild irAEs with unnecessary immunosuppression can compromise antitumor efficacy. REMS programs and institutional credentialing increasingly require documented competency in irAE management for providers administering ICIs.

Checkpoint A: Pre-Draft Intake (Mandatory)

1. Which immune checkpoint inhibitor(s) is the patient receiving? (Default: specify agent, dose, schedule)
2. Is this monotherapy or combination ICI (e.g., ipilimumab + nivolumab)? (Default: specify — combination has higher irAE rates)
3. What cycle is the patient currently on? (Default: specify)
4. What suspected irAE is being evaluated? (Default: describe symptoms and organ system)
5. What are the baseline organ function values (pre-treatment TSH, LFTs, creatinine, glucose, cortisol)? (Default: review)
6. Does the patient have pre-existing autoimmune conditions? (Default: document)
7. Is the patient receiving concurrent corticosteroids or immunosuppressive medications? (Default: document)
8. Has the patient had prior irAEs on this or previous ICI therapy? (Default: document)

Documents to Request

• Baseline labs (CBC, CMP, TSH, free T4, cortisol, LFTs, lipase, troponin, BNP) pre-ICI initiation
• Current labs for the suspected irAE
• ASCO/NCCN irAE management guideline for the specific organ system
• Prior irAE documentation with grade and management
• Current imaging if organ-specific irAE suspected (CT chest for pneumonitis, MRI brain for hypophysitis)
• Autoimmune disease history with prior immunosuppressive medications
• Medication list (corticosteroids, other immunosuppressants)
• EKG and troponin if cardiac irAE suspected

Step 1: Recognize and Grade the irAE

Common irAEs by organ system and timeline:

Grade irAEs using CTCAE v5.0 and ASCO/NCCN organ-specific algorithms. Key grading examples:

• Colitis: Grade 1 (<4 stools/day over baseline), Grade 2 (4–6 stools/day), Grade 3 (≥7 stools/day, peritoneal signs), Grade 4 (perforation, hemorrhage)
• Hepatitis: Grade 1 (AST/ALT 1–3× ULN), Grade 2 (3–5× ULN), Grade 3 (5–20× ULN), Grade 4 (>20× ULN)
• Pneumonitis: Grade 1 (radiographic only, asymptomatic), Grade 2 (symptomatic, limiting instrumental ADL), Grade 3 (severe, limiting self-care ADL, O2 indicated), Grade 4 (life-threatening respiratory compromise)

Step 2: Apply Grade-Based Management Algorithm

Universal irAE management framework (adapt per organ-specific guidelines):

Organ-specific management notes:

• Colitis: Infliximab 5 mg/kg IV for steroid-refractory colitis (avoid in hepatitis). Vedolizumab as alternative.
• Hepatitis: Mycophenolate for steroid-refractory hepatitis (do NOT use infliximab — hepatotoxic).
• Pneumonitis: Bronchoscopy with BAL to rule out infection before escalating immunosuppression.
• Myocarditis: EMERGENCY — consult cardiology immediately. High-dose methylprednisolone 1g IV daily × 3–5 days. Cardiac monitoring. Consider IVIG, infliximab, or abatacept for refractory cases.
• Endocrinopathies: Hormone replacement (levothyroxine for hypothyroidism, hydrocortisone for adrenal insufficiency). ICI can often be continued with hormone replacement.

Step 3: Manage Steroid Taper and ICI Rechallenge

Steroid taper protocol:

1. Once irAE improved to Grade ≤1, begin taper
2. Reduce by 10mg prednisone equivalent per week (for starting doses >40mg)
3. Below 20mg, reduce by 5mg per week
4. Below 10mg, reduce by 2.5mg per week
5. Total taper duration: minimum 4–6 weeks; extend for severe irAEs
6. If symptoms recur during taper, return to the previous effective dose and hold for 1–2 weeks before reattempting taper

ICI rechallenge considerations:

• Grade 1–2 irAEs: generally safe to rechallenge after resolution to Grade ≤1
• Grade 3 irAEs: rechallenge may be considered with caution; increased monitoring required
• Grade 4 irAEs: permanent discontinuation recommended (except for endocrinopathies managed with replacement)
• Myocarditis, pneumonitis ≥Grade 3, or neurologic irAEs ≥Grade 3: do NOT rechallenge
• Anti-CTLA-4 irAEs can be followed by anti-PD-1 monotherapy (switch, not rechallenge) in selected cases

Step 4: Document irAE Management

For each irAE event, document:

1. Organ system and specific irAE per CTCAE v5.0 term
2. Grade assignment with supporting lab values or clinical findings
3. Date of onset relative to ICI cycle number
4. ICI action (continued, held, permanently discontinued)
5. Immunosuppression — agent, dose, start date, taper schedule
6. Specialist consultations obtained (endocrinology, GI, pulmonology, cardiology)
7. Response to treatment — date of improvement, current grade
8. Rechallenge decision with rationale
9. Long-term monitoring plan — some irAEs require lifelong monitoring (e.g., thyroid function after thyroiditis)

Checkpoint B: Post-Draft Alignment (Mandatory)

1. Is the irAE graded using CTCAE v5.0 criteria specific to the organ system?
2. Does the management follow ASCO/NCCN irAE management guideline algorithms?
3. Has infection been ruled out before attributing symptoms to irAE (especially for pneumonitis and colitis)?
4. Is the steroid taper duration adequate (minimum 4–6 weeks)?
5. Is the rechallenge decision documented with rationale and consistent with safety guidelines?

Quality Audit

• Specific ICI agent, dose, and schedule documented
• Baseline labs (TSH, LFTs, creatinine, glucose) obtained pre-treatment
• irAE identified with CTCAE v5.0 grading and supporting data
• Management follows ASCO/NCCN organ-specific irAE guideline
• Infection ruled out before immunosuppression escalation
• Corticosteroid dose appropriate for the irAE grade
• Steroid taper plan documented with minimum 4–6 week duration
• Second-line immunosuppression (infliximab, mycophenolate) appropriately selected per organ system
• Specialist consultation obtained for Grade ≥3 irAEs
• ICI rechallenge decision documented with rationale
• Endocrine irAEs have hormone replacement plan documented
• Long-term monitoring plan for persistent or chronic irAEs
• Cardiac irAE managed as emergency with cardiology involvement
• Patient education on irAE symptoms and when to seek care documented

Guidelines

• Baseline labs (TSH, LFTs, creatinine, cortisol, glucose) must be obtained before first ICI dose — you cannot grade a toxicity without knowing baseline values
• Combination ICI (ipilimumab + nivolumab) has 2–3× higher irAE rates than monotherapy — monitor more frequently
• irAEs can occur months after ICI discontinuation — maintain surveillance for at least 12 months after the last dose
• Never attribute new symptoms to "expected side effects" without systematic irAE evaluation — any new organ dysfunction on ICI should be considered irAE until proven otherwise
• Infliximab is contraindicated for immune-related hepatitis — use mycophenolate instead
• Endocrine irAEs (hypothyroidism, adrenal insufficiency) are typically permanent and require lifelong hormone replacement
• Immune-related myocarditis is a medical emergency — troponin and EKG should be checked urgently for any cardiac symptoms
• Development of certain irAEs (vitiligo in melanoma, thyroiditis) may correlate with better antitumor response — document this for prognostic context